Accumulating evidence suggests that the hyperactivation of STAT3 within tumors and immune cells shapes the tumor microenvironment and STAT3 causes tumor-promoting inflammation while impairing antitumor immunity.[43,44] Although STAT3-targeted therapeutics have been developed, challenges continue to emerge. Here, STAT3 is linked to neoplasm.